Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Gain in-depth knowledge on oral selective estrogen receptor degrader (SERD) therapy and strategies for integrating SERDs for HR+/HER2- breast cancer cases in your clinical practice through an on-demand webcast, downloadable slides, and a podcast.

Share

Program Content

Activities

Evidence for SERDs Tx
The Expanding Evidence Base for Oral SERDs and Other ER-Targeting Agents
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2024

Expires: May 29, 2025

Future for SERD Tx
Possibilities for the Future of SERD Therapy for HR+/HER2- Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2024

Expires: May 29, 2025

SERD for ET Resistance
Steps Toward Precision Oncology: Role of SERD in Attacking Endocrine Resistance in HR+/HER2- Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2024

Expires: May 29, 2025

Activities

SERDs in Breast Cancer at ASCO 2024
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 18, 2024

Expires: June 17, 2025

Activities

Spotlight on SERDs in Breast Cancer
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: July 22, 2024

Expires: July 21, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly